Skip to Content Contact Us
Clinical Trial Report

Amendis successfully completed its first clinical study on oral cavity cancer patients to predict metastasis to the neck

February 14, 2022

As part of the clinical study, which was conducted at the Hadassah University Hospital-Ein Kerem under Helsinki approval, cancerous tissues from the tongue of head and neck cancer patients were examined.

Read More
Melanima Nautre

Overcoming drug resistance in the treatment of Melanoma

June 10, 2021

Dr. Nataly Kravchenko-Balasha and her colleagues have received further recognition of their important research into the fight against cancer, with the publication of their latest article in the prestigious journal npj Precision Oncology, published by Spri


Read More
Shamir Kaminsky

Adv. Shamir Kaminsky has been appointed to the position of Vice President for Regulatory Affairs and Medical Insurance in Amendis

December 23, 2020

Amendis has appointed Adv. Shamir Kaminsky as Vice President for Regulatory Affairs and Medical Insurance. Adv. Kaminsky is a consultant and lecturer in the fields of insurance and medical innovation in Israel and around the world.

Read More
Dr. Nataly Kravchenko Balasha

The Next Good News Concerning Cancer Treatment Will Come Out of Israel

December 13, 2020

Israel has been blessed with an abundance of talented, innovative and groundbreaking researchers. Goldman Bio has recognized the opportunity to invest in early-stage companies in the field of oncology, combining the creation of economic value with activities for the common good.


Read More
medpnc spinoff prize

MEDPNC has been selected as a “One to Watch” company in 2020 Spinoff Prize

July 5, 2020

MEDPNC has been selected as one of the 32 “one to watch” companies in this year’s prestigious Spinoff Prize, which is organized by Nature Research and Merck KGaA, Germany.

The prize aims to provide visibility and support for academic entrepreneurs and their companies, worldwide.

Read More
equity investments in hi tech companies

Government approved a plan to provide a state guarantee for equity invested by institutional investors in high-tech companies

June 7, 2020

Goldman Bio’s innovative creation of a Limited Partnership investing in Israeli biopharma R&D, which is to be traded on the TASE, has just received further indication of its significance by way of the Israeli Government’s approval of a program to promote institutional investment in Israeli high-tech companies.


Read More
Back top top